MIRXES-B(02629) and Watson have entered into a memorandum of understanding to establish an RNA-centered platform for preventive and precision healthcare.

MIRXES-B(02629) announced that the company has recently entered into a Memorandum of Understanding with Yunnan Walvax Biotechnology Technology Co., Ltd. (Walvax), whereby the contracting parties have agreed to leverage their respective complementary strengths to establish a strategic partnership focusing on creating a RNA-centered preventive and precision medical platform. This partnership will cover collaborative development, clinical trials, registration, sales, and distribution. The duration of the Memorandum of Understanding is two years from the signing date. The scope of cooperation outlined in the Memorandum of Understanding includes: (a) Establishing a RNA-centered preventive and precision medical excellence research center in Singapore, leveraging the company's proprietary disease RNA database and Walvax's mRNA technology to advance research and translation of RNA-centered diagnostic products, vaccines, and therapeutics; (b) Expediting clinical trials and regulatory approvals for existing and pipeline products of diagnostic products, vaccines, and therapeutics in the ASEAN region; (c) Setting up a sales and distribution platform in Singapore for existing and pipeline products, focusing on serving the ASEAN and specific international markets; and (d) Establishing a supply chain in Singapore to coordinate end-stage production, quality, and commercial deployment of existing and pipeline products. The Board of Directors believes that this partnership with Walvax can create significant strategic value, further consolidating the company's position as a key player in the rapidly growing RNA diagnostic and therapeutic ecosystem in the region, expanding the company's product portfolio of early detection and preventive solutions, and accelerating revenue growth. This new RNA-centered preventive and precision medical platform will enable global institutions to collaborate with the company and Walvax in seizing and expanding regional opportunities, strategically entering the ASEAN and specific international markets. This partnership is also expected to facilitate cross-border investment and cooperation opportunities, enhance corporate visibility, deepen research and development capabilities, and contribute to the long-term development and revenue diversification of the group.